171 related articles for article (PubMed ID: 22113496)
1. Constitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor.
Lucs AV; Wu R; Mullooly V; Abramson AL; Steinberg BM
Mol Med; 2012 Mar; 18(1):244-9. PubMed ID: 22113496
[TBL] [Abstract][Full Text] [Related]
2. T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.
Rosenthal DW; DeVoti JA; Steinberg BM; Abramson AL; Bonagura VR
Mol Med; 2012 Dec; 18(1):1338-45. PubMed ID: 23019074
[TBL] [Abstract][Full Text] [Related]
3. Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Rojas-Lechuga MJ; Remacha J; González-Sánchez N; Grau JJ; Castillo P; Haag O; Vilaseca I
Int J Pediatr Otorhinolaryngol; 2020 Oct; 137():110194. PubMed ID: 32658799
[TBL] [Abstract][Full Text] [Related]
4. Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression.
Wu R; Abramson AL; Symons MH; Steinberg BM
Int J Cancer; 2010 Nov; 127(9):2230-7. PubMed ID: 20131316
[TBL] [Abstract][Full Text] [Related]
5. Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.
James EA; DeVoti JA; Rosenthal DW; Hatam LJ; Steinberg BM; Abramson AL; Kwok WW; Bonagura VR
J Immunol; 2011 Jun; 186(11):6633-40. PubMed ID: 21531896
[TBL] [Abstract][Full Text] [Related]
6. Altered Monocyte and Langerhans Cell Innate Immunity in Patients With Recurrent Respiratory Papillomatosis (RRP).
Israr M; DeVoti JA; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Front Immunol; 2020; 11():336. PubMed ID: 32210959
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical implications of low-risk human papillomavirus among patients with recurrent respiratory papillomatosis in Rio de Janeiro, Brazil.
Figueiredo MC; Justino MC; Delmonico L; Silvestre RT; de Castro TL; Dos Santos Moreira A; Macedo JMB; da Costa Carvalho MDG; Scherrer L; de Medeiros Lima DJM; Alves G; Ornellas MH
Auris Nasus Larynx; 2019 Aug; 46(4):570-575. PubMed ID: 30581074
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas.
Wu R; Coniglio SJ; Chan A; Symons MH; Steinberg BM
Mol Med; 2007; 13(3-4):143-50. PubMed ID: 17592548
[TBL] [Abstract][Full Text] [Related]
10. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.
Bonagura VR; Hatam LJ; Rosenthal DW; de Voti JA; Lam F; Steinberg BM; Abramson AL
APMIS; 2010 Jun; 118(6-7):455-70. PubMed ID: 20553528
[TBL] [Abstract][Full Text] [Related]
11. Human papillomatosis genotyping and severity in patients with recurrent respiratory papillomatosis.
Intakorn P; Sonsuwan N
J Med Assoc Thai; 2014 Jun; 97 Suppl 6():S136-41. PubMed ID: 25391185
[TBL] [Abstract][Full Text] [Related]
12. Recurrent respiratory papillomatosis: A state-of-the-art review.
Fortes HR; von Ranke FM; Escuissato DL; Araujo Neto CA; Zanetti G; Hochhegger B; Souza CA; Marchiori E
Respir Med; 2017 May; 126():116-121. PubMed ID: 28427542
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
Antoniou K; Malamas M; Drosos AA
Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous 18F-FDG uptake in recurrent respiratory papillomatosis.
Yu JP; Barajas RF; Olorunsola D; Sugrue LP; Hernandez-Pampaloni M
Clin Nucl Med; 2013 May; 38(5):387-9. PubMed ID: 23486321
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
16. Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis.
Bentley PL; Coulter MJ; Nelson BL
Head Neck Pathol; 2019 Jun; 13(2):235-238. PubMed ID: 29594918
[TBL] [Abstract][Full Text] [Related]
17. Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.
DeVoti J; Hatam L; Lucs A; Afzal A; Abramson A; Steinberg B; Bonagura V
Mol Med; 2014 Aug; 20(1):372-80. PubMed ID: 24950037
[TBL] [Abstract][Full Text] [Related]
18. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Limsukon A; Susanto I; Soo Hoo GW; Dubinett SM; Batra RK
Chest; 2009 Sep; 136(3):924-926. PubMed ID: 19736197
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Kuipers GK; Slotman BJ; Wedekind LE; Stoter TR; Berg Jv; Sminia P; Lafleur MV
Int J Radiat Biol; 2007 Oct; 83(10):677-85. PubMed ID: 17729162
[TBL] [Abstract][Full Text] [Related]
20. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
Bedoya A; Glisinski K; Clarke J; Lind RN; Buckley CE; Shofer S
Am J Case Rep; 2017 Jul; 18():842-846. PubMed ID: 28757601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
